Therapeutic imprinting of the immune system: towards a remission of AIDS in primates?

Retrovirology

Enrico Garaci¹  Andrea Savarino² 

[1]Istituto Superiore di Sanità, Viale Regina Elena, Rome, Italy

[2]Department of Infectious, Parasitic and Immune-mediated Diseases, Istituto Superiore di Sanità, Viale Regina Elena, Rome 299 00161, Italy

关键词: Anti-reservoir;    Buthionine sulfoximine (BSO);    Auranofin;    Maraviroc;    Central memory CD4⁺ T-cells;    Antiretroviral therapy;    Functional cure;    Macaque AIDS model;   

Others  :  1209267
DOI  :  10.1186/1742-4690-9-75

 received in 2012-07-10, accepted in 2012-09-02,  发布年份 2012

【 摘 要 】

Our inability to cure HIV/AIDS is related to the ability of the virus to establish reservoirs during treatment. In order to develop new strategies, it is certainly essential that a suitable animal model be implemented. In the recent work of Shytaj et al., it has been possible to inhibit viral replication to levels below the assay detection limit in the macaque AIDS model. Moreover, different therapeutic regimens applied to the rhesus macaque AIDS model (herein reviewed), including ours, are starting to show the potential to induce, following therapy suspension, conditions reminiscent of a drug-free control of the infection.

【 授权许可】

   
2012 Savarino and Garaci; licensee BioMed Central Ltd.

【 图 表 】

Figure 1.

【 参考文献 】

• [1]Palmer S, Josefsson L, Coffin JM: HIV reservoirs and the possibility of a cure for HIV infection. J Intern Med 2011, 270:550-560.
• [2]Chomont N, DaFonseca S, Vandergeeten C, Ancuta P, Sékaly RP: Maintenance of CD4+ T-cell memory and HIV persistence: keeping memory, keeping HIV. Curr Opin HIV AIDS 2011, 6:30-36.
• [3]Deeks SG, Autran B, Berkhout B, Benkirane M, Cairns S, Chomont N, Chun TW, Churchill M, Mascio MD, Katlama C, Lafeuillade A, Landay A, Lederman M, Lewin SR, Maldarelli F, Margolis D, Markowitz M, Martinez-Picado J, Mullins JI, Mellors J, Moreno S, O'Doherty U, Palmer S, Penicaud MC, Peterlin M, Poli G, Routy JP, Rouzioux C, Silvestri G, Stevenson M, et al.: Towards an HIV cure: a global scientific strategy. Nat Rev Immunol 2012, 12:607-614.
• [4]Savarino A, Mai A, Norelli S, El Daker S, Valente S, Rotili D, Altucci L, Palamara AT, Garaci E: "Shock and kill" effects of class I-selective histone deacetylase inhibitors in combination with the glutathione synthesis inhibitor buthionine sulfoximine in cell line models for HIV-1 quiescence. Retrovirology 2009, 6:52. BioMed Central Full Text
• [5]Lewis MG, DaFonseca S, Chomont N, Palamara AT, Tardugno M, Mai A, Collins M, Wagner WL, Yalley-Ogunro J, Greenhouse J, Chirullo B, Norelli S, Garaci E, Savarino A: Gold drug auranofin restricts the viral reservoir in the monkey AIDS model and induces containment of viral load following ART suspension. AIDS 2011, 25:1347-1356.
• [6]Deere JD, Schinazi RF, North TW: Simian immunodeficiency virus macaque models of HIV latency. Curr Opin HIV AIDS 2011, 6:57-61.
• [7]Lewis MG, Norelli S, Collins M, Barreca ML, Iraci N, Chirullo B, Yalley-Ogunro J, Greenhouse J, Titti F, Garaci E, Savarino A: Response of a simian immunodeficiency virus (SIVmac251) to raltegravir: a basis for a new treatment for simian AIDS and an animal model for studying lentiviral persistence during antiretroviral therapy. Retrovirology 2010, 7:21. BioMed Central Full Text
• [8]Shytaj IL, Norelli S, Chirullo B, Della Corte A, Collins M, Yalley-Ogunro J, Greenhouse J, Iraci N, Acosta EP, Barreca ML, Lewis MG, Savarino A: A highly intensified ART regimen induces long-term viral suppression and restriction of the viral reservoir in a simian AIDS model. PLoS Pathog 2012, 8:e1002774.
• [9]Gutiérrez C, Díaz L, Vallejo A, Hernández-Novoa B, Abad M, Madrid N, Dahl V, Rubio R, Moreno AM, Dronda F, Casado JL, Navas E, Pérez-Elías MJ, Zamora J, Palmer S, Muñoz E, Muñoz-Fernández MÁ, Moreno S: Intensification of antiretroviral therapy with a CCR5 antagonist in patients with chronic HIV-1 infection: effect on T cells latently infected. PLoS One 2011, 6:e27864.
• [10]Ananworanich J, Schuetz A, Vandergeeten C, Sereti I, de Souza M, Rerknimitr R, Dewar R, Marovich M, van Griensven F, Sekaly R, Pinyakorn S, Phanuphak N, Trichavaroj R, Rutvisuttinunt W, Chomchey N, Paris R, Peel S, Valcour V, Maldarelli F, Chomont N, Michael N, Phanuphak P, Kim JH, RV254/SEARCH 010 Study Group: Impact of multi-targeted antiretroviral treatment on gut T cell depletion and HIV reservoir seeding during acute HIV infection. PLoS One 2012, 7:e33948.
• [11]Savarino A, Lewis MG, Shytaj IL, Chirullo B, Norelli S, Sgarbanti R, Barreca ML, Sgarbanti M, Palamara AT, Garaci E: Eradication trials in SIVmac251-infected macaques [abstract]. Global Antiviral Journal 2011, 7(Suppl. 2):3-4.
• [12]Van Rompay KK, Trott KA, Jayashankar K, Geng Y, Labranche CC, Johnson JA, Landucci G, Lipscomb J, Tarara RP, Canfield DR, Heneine W, Forthal DN, Montefiori D, Abel K: Prolonged tenofovir treatment of macaques infected with K65R reverse transcriptase mutants of SIV results in the development of antiviral immune responses that control virus replication after drug withdrawal. Retrovirology 2012, 9:57. BioMed Central Full Text
• [13]Benlhassan-Chahour K, Penit C, Dioszeghy V, Vasseur F, Janvier G, Rivière Y, Dereuddre-Bosquet N, Dormont D, Le Grand R, Vaslin B: Kinetics of lymphocyte proliferation during primary immune response in macaques infected with pathogenic simian immunodeficiency virus SIVmac251: preliminary report of the effect of early antiviral therapy. J Virol 2003, 77:12479-12493.
• [14]Rong L, Perelson AS: Modeling latently infected cell activation: viral and latent reservoir persistence, and viral blips in HIV-infected patients on potent therapy. PLoS Comput Biol 2009, 5:e1000533.